Partners

 

 

Levena BioPharma

Lead Partner

AtLevena BioPharma,we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND.  Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.

 

 

 

MabPlex

Senior Partner

MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.

 

 

Heidelberg Pharma

Partner

Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.

www.heidelberg-pharma.com

 

 

Iksuda Therapeutics

Partner

Iksuda Therapeutics (formally Glythera) is a pre-clinical stage company developing ADCs for difficult to treat solid tumours. Our ADCs are centered around our proprietary PermaLInk® conjugation platform which provides conjugation stability by design.

Through PermaLink, we aim to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA damaging payloads, combined with clinically relevant targets.

Through our collaborations and partnerships, we are building a pipeline of superior ADCs with the goal of improving the lives of patients living with cancer.

www.iksuda.com

 

 

ADC Bio

Exhibitor

ADC Bio is an innovative biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of ADCs. The company are specialists in state-of-the-art bio-conjugation techniques and cytotoxin drug-linker synthesis, assisting drug developers to deliver their next generation ADCs. Our proprietary ‘Lock-Release’ technology aims to become a new paradigm in the way ADCs are developed and manufactured by providing fast, simple and robust conjugation processes

www.adcbio.com

 

 

BrightGene

Exhibitor